More study data available!
Data has been uploaded for 3 studies including:
- Pre-clinical studies:
- CAVD 465 (Überla) — NHP study evaluates T helper cell responses after adenoviral vector and virus-like particle prime/boost regimens.
- CAVD 719 and CAVD 720 (Pettit) — Mouse studies compare the half-life of optimized PGT121 and PGDM1400 molecules with the parental (non-LS) molecules.
Click on the study page links below for Protocol Team reports, data summaries, and more details about the studies.
Data was uploaded for the following studies:
|
Name & Description |
Data Added |
Type |
PI |
Strategy |
|
CAVD 465 is a non-human primate challenge study to evaluate and compare the immunogenicity of priming with adenoviral vectors encoding FIV Gag, SIV Gag, HIV Env or a control antigen (RSV-F) and boosting with VLPs containing FIV Gag and HIV Env (FIVHenv) or SIV Gag and HIV Env (SIVHenv) |
BAMA, ICS, NAB |
Pre-Clinical NHP |
Klaus Überla |
Combo: Vector & VLP vaccines |
|
CAVD 719 is a PK study of optimized PGT121 molecules in hemizygous FcRn Tg276 mice |
PK MAB |
Pre-Clinical Non-NHP |
Dean Pettit |
Prophylactic neutralizing Ab |
|
CAVD 720 is a PK study of optimized PGDM1400 molecules in hemizygous FcRn Tg276 mice |
PK MAB |
Pre-Clinical Non-NHP |
Dean Pettit |
Prophylactic neutralizing Ab |